The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.

The landscape of targeted therapy continues to rapidly evolve, and pharmacists play an integral role on the interprofessional health care team. It is important for pharmacists to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.

The landscape of targeted therapy continues to rapidly evolve, and pharmacists play an integral role on the interprofessional health care team. It is important for pharmacists to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatobiliary cancers.

To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.

Keeping clinicians up-to-date with the most recent NCCN Guidelines for Hepatobiliary Cancers recommendations and emerging therapies can help improve clinical decision-making and patient outcomes.

The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.

Incidence and mortality rates for most cancers are declining; however, the incidence and mortality rates for liver cancer are increasing. A thorough understanding of the different approaches to treatment can help clinicians identify the optimal treatment strategy. Keeping clinicians abreast of new developments in the field can better inform clinical decision-making.

While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.